ITC institutes Investigation No. 337-TA-1377 on tirzepatide products
The U.S. International Trade Commission opened a case in November 2023 targeting unauthorized tirzepatide products sold online, a step toward blocking imports of compounded or counterfeit versions of Eli Lilly's drug.
The U.S. International Trade Commission (ITC) voted to institute Investigation No. 337-TA-1377 on November 20, 2023, opening a formal case into imported products that contain or claim to contain tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound [1][2]. The notice was published in the Federal Register on November 27, 2023 [1].
The case stems from a complaint Eli Lilly and Company filed on October 19, 2023, and later supplemented on November 10, 2023 [1][2]. Lilly's complaint alleges that the imported products violate Section 337 of the Tariff Act of 1930 by infringing U.S. Trademark Registration No. 6,809,369, by falsely stating where the products came from, and by making false or misleading advertising claims [1]. Lilly asked the ITC to issue either a general exclusion order, which would block all infringing imports regardless of source, or a more limited exclusion order aimed at specific companies, plus cease and desist orders against those companies [1][2].
The ITC named eleven respondents in the case, including U.S.-based sellers such as Arctic Peptides LLC of Ankeny, Iowa, Strate Labs LLC of Spring, Texas, Triggered Supplements LLC of Clearwater, Florida, and two firms in Cedar Grove, New Jersey — Supopeptide and Unewlife — along with overseas sellers in Hong Kong, the United Kingdom, Poland, Spain, and China [2]. Instituting the investigation does not mean the ITC has decided the case on its merits [2]. Instead, the Commission's Chief Administrative Law Judge assigns the matter to an administrative law judge, who holds an evidentiary hearing and issues an initial determination on whether a violation occurred; that determination is then subject to Commission review [2]. The Commission was required to set a target date for completing the investigation within 45 days of institution [2].
Why it matters for patients
This case is part of a broader effort to police the market for tirzepatide products sold outside the regulated pharmaceutical supply chain, including items marketed as "research peptides" or compounded alternatives that patients might buy online without a prescription tied to a licensed pharmacy. The complaint specifically flags trademark infringement and false or misleading advertising, meaning some products may not accurately describe their contents or origin [1]. For someone taking or considering a GLP-1 medication, the case is a reminder that not everything sold online under a tirzepatide-related name has gone through the same oversight as products dispensed through licensed pharmacies. The sources here do not say whether any tested products actually failed to contain tirzepatide or contained something else; the ITC complaint is about trademark and advertising violations, not a public statement about drug safety testing results.
It's also worth noting what this case is not: an FDA drug-safety action. The ITC handles trade law, particularly unfair import practices, and its remedies are limited to blocking imports and ordering companies to stop specific conduct — not recalling products already in U.S. commerce or issuing clinical warnings.
What happens next
According to the docket history included with the Federal Register notice, the investigation moved through several further stages after institution. The Commission ruled on motions to amend the complaint on May 28, 2024, and again on June 18, 2024 [1]. It then sought public comment on the case's effect on the public interest on December 13, 2024 [1]. On January 28, 2025, the Commission declined to review an initial determination that had found respondents in violation of Section 337, and asked for further submissions on remedy, public interest, and bonding [1]. The investigation concluded on April 15, 2025, when the Commission issued a general exclusion order, a limited exclusion order, and cease and desist orders, formally terminating the case [1]. Details of what those final orders require, and how they are being enforced, are not covered in the sources reviewed for this article.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.